Effects of inositol on ovarian function and metabolic factors in women with PCOS: A randomized double blind placebo-controlled trial

European Review for Medical and Pharmacological Sciences

Volumn 7, Issue 6, 2003, Pages 151-159

  Gerli, S ^a   Mignosa, M ^a   Di Renzo, G C ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Inositol; Insulin resistance; Ovarian function; PCOS

Indexed keywords

ESTRADIOL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL; INSULIN; PLACEBO; PROGESTERONE;

ADULT; ARTICLE; BODY MASS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LUTEAL PHASE; MAJOR CLINICAL STUDY; OBESITY; OLIGOMENORRHEA; OVARY FOLLICLE MATURATION; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE; OVULATION; PATIENT COMPLIANCE; PROGESTERONE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INOSITOL; OBESITY; OLIGOMENORRHEA; OVARIAN FUNCTION TESTS; OVARY; POLYCYSTIC OVARY SYNDROME;

EID: 2442639184     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Dunaif A, Givens JR, Haseltine F, Merriam GR (eds). The Polycystic Ovary Syndrome. Blackwell Scientific, Cambridge, MA, 1992.
2. Franks S. Polycystic ovary syndrome. N Engl J Med 1995; 333: 853-861.
3. Polson DW, Wadsworth J, Adams J, Franks S. Polycystic ovaries-a common finding in normal women. Lancet 1998; 1: 870-872.
4. Pettersson F, Fries H, Nillius SJ. Epidemiology of secondary amenorrhea. Am J Obstet Gynecol 1973; 117: 80-86.
5. Hull MGR. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies.Gynecol Endocrinol 1987; 1: 235-245.
6. Goldzieher JW, Green JA. The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 1962; 22: 325-338.
7. Burghen GA, Givens JR, Kitabchi AE. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J Clin Endocrinol Metab 1980; 50: 113-116.
8. Dunaif A, Hoffman AR. Insulin resistance and hyperandrogenism: clinical syndromes and possible mechanisms. In: Pancheri P, Zichella L (eds) Biorhythms and Stress in the Physiopathology of Reproduction. Hemisphere Publishin Co, Washington, DC, 1998; pp 293-317.
9. Pugeat M. Genetics of the polycystic ovarian syndrome and therapeutic perspectives. Rev Med Chir Soc Med Nat Iasi 2000; 104: 11-19.
10. Laboureau-Soares Barbosa S, Rodien P, Rohmer V. 2002 Polycystic ovary syndrome: treatment with insulin-sensitizing agents. Ann Endocrinol (Paris) 2002; 63: 31-35.
11. Iuorno MJ, Nestler JE. Insulin-lowering drugs in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001; 28: 153-164.
12. Fleming R, McQueen D, Yates RWS, Coutts JRT. Spontaneous follicular and luteal function in infertile women with oligomenorrhoea: role of luteinizing hormone. Clin Endocrinol (Oxf) 1995; 43: 735-739.
13. Adams J, Polson JW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J 1986; 293: 355-359.
14. White DM, Polson DW, Kiddy D, et al. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996; 81: 3821-3824.
15. Pirwany IR, Yates RW, Cameron IT, Fleming R. Effects of the insulin sensitizing drug metformin on ovarian function, follicular growth and ovulation rate in obese women with oligomenorrhoea. Hum Reprod 1999; 14: 2963-2968.
16. World Health Organization 1989 Measuring Obesity: classification and distribution of anthropometric data. Copenhagen: WHO (Nutr UD, EUR/ICP/NUT 125).
17. Lipid Research Clinics Program. Lipid and lipoprotein analysis, manual of laboratory operations, 1. Bethesda, MD: National Institutes of Health, DHEW Publications; 1975; 75.
18. McConway MG, Johnson D, Kelly A, Griffin D, Smith J, Wallace AM. Differences in circulating concentrations of total, free and bound leptin relate to gender and body composition in adult humans. Ann Clin Biochem 2000; 37: 717-723.
19. Nestler JE, Jakubowicz DJ, Iuorno MJ. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J Pediatr Endocrinol Met 2000; 13 (Suppl 5): 1295-1298.
20. Nestler JE. Inositolphosphoglycans (IPGs) as mediators of insulin's steroidogenic actions. J Basic Clin Physiol Pharmacol 1998; 9: 197-204.
21. Larner J, Allan G, Kessler C, Reamer P, Gunn R, Huang LC. Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. J Basic Clin Physiol Pharmacol 1998; 9: 127-137.
22. Gasic A, Bodenburg Y, Nagami M, Green A, Urban R.J. Troglitazone inhibits progesterone production in porcine granulosa cells. Endocrinology 1998; 139: 4962-4966.
23. Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in the reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13: 1502-1505.